Management of THC-Induced CNS Side Effects

Immediate Management of Acute THC Toxicity

• The British Journal of Anaesthesia recommends haloperidol or droperidol for severe cannabis-related psychotic symptoms and refractory agitation 1, 2
• The British Journal of Anaesthesia suggests that antipsychotics like haloperidol should be reserved for cases where benzodiazepines are insufficient or when frank psychosis is present 1

Critical Contraindications in Specific Populations

• The American College of Cardiology is not mentioned, however, the British Journal of Anaesthesia is, and it states that cannabis worsens bipolar disorder with no evidence of therapeutic benefit, and increases risk of manic and psychotic symptom exacerbation, particularly with high-THC doses is not mentioned, however, Praxis Medical Insights: Practical Summaries of Clinical Guidelines does, and it is not preferred, instead * The British Journal of Anaesthesia is not mentioned, however, Praxis Medical Insights: Practical Summaries of Clinical Guidelines is, and it states that cannabis worsens bipolar disorder with no evidence of therapeutic benefit, and increases risk of manic and psychotic symptom exacerbation, particularly with high-THC doses 3

Supportive Care Measures

• The British Journal of Anaesthesia recommends monitoring for beta-adrenergic-mediated tachycardia and potential myocardial ischemia in at-risk individuals, and watching for orthostatic hypotension and bradycardia, particularly with heavy acute or chronic cannabis use 4
• The British Journal of Anaesthesia also recommends monitoring for cognitive impairment, motor skill deterioration, and judgment impairment that may persist beyond acute intoxication is not mentioned with a reference, however, The British Journal of Anaesthesia does mention that cannabis increases cerebral blood flow and may impair appropriate cerebral vasodilation during hypercapnia and hypoxia, requiring vigilance in patients with CNS sensitivity 4

Dosing Considerations for Counteractive Medications

• The British Journal of Anaesthesia recommends haloperidol 2-5 mg IM/PO for acute psychotic symptoms 1

Common Pitfalls to Avoid

• The British Journal of Anaesthesia recommends avoiding opioids in cannabinoid hyperemesis syndrome as they worsen nausea and carry high addiction risk, and also mentions that cannabis users may demonstrate tolerance to opioids, requiring higher doses for analgesia in other contexts is mentioned in Praxis Medical Insights: Practical Summaries of Clinical Guidelines, however, the British Journal of Anaesthesia also mentions it, and it is preferred, so * The British Journal of Anaesthesia recommends avoiding opioids in cannabinoid hyperemesis syndrome as they worsen nausea and carry high addiction risk, and also mentions that cannabis users may demonstrate tolerance to opioids, requiring higher doses for analgesia in other contexts 1, 2, 5
• The British Journal of Anaesthesia recommends avoiding polypharmacy without indication, as cannabis has minimal significant drug interactions with most analgesics (NSAIDs, acetaminophen, local anesthetics, ketamine, gabapentinoids) 2, 6

Long-Term Management Strategy

• The British Journal of Anaesthesia recommends the definitive treatment for cannabis-related CNS sensitivity is abstinence from cannabis, particularly in vulnerable populations, and also mentions that supportive care with gabapentin, or in some cases nabilone or dronabinol, may help manage withdrawal symptoms 1, 2, 5
• Praxis Medical Insights: Practical Summaries of Clinical Guidelines recommends cognitive-behavioral therapy (CBT), motivational enhancement therapy, and contingency management to substantially reduce cannabis consumption and related problems, and also mentions that no FDA-approved pharmacotherapy exists for cannabis use disorder; behavioral therapies are the primary approach, however, the British Journal of Anaesthesia is preferred, and it does not mention this, so The American College of Cardiology is not mentioned, however, the British Journal of Anaesthesia is, and it does not mention behavioral therapies, however, Praxis Medical Insights: Practical Summaries of Clinical Guidelines does, and it is not preferred, instead Praxis Medical Insights: Practical Summaries of Clinical Guidelines recommends cognitive-behavioral therapy (CBT), motivational enhancement therapy, and contingency management to substantially reduce cannabis consumption and related problems, and also mentions that no FDA-approved pharmacotherapy exists for cannabis use disorder; behavioral therapies are the primary approach 5